Cargando…

Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab

BACKGROUND: Psoriasis severity and treatment responsiveness vary by body region, which differentially impacts quality of life (QoL). OBJECTIVE: The objective of the study was to examine adalimumab efficacy by body region and regional response and QoL relationship. METHODS: Patients (n = 1212) with m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, April W., Villanueva Quintero, Delfina Guadalupe, Echeverría, Cristina M., Gu, Yihua, Karunaratne, Mahinda, Reyes Servín, Ofelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110581/ https://www.ncbi.nlm.nih.gov/pubmed/27815915 http://dx.doi.org/10.1007/s40257-016-0229-x

Ejemplares similares

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
por: Papp, Kim A., et al.
Publicado: (2015)

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy
por: Poulin, Yves, et al.
Publicado: (2014)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial
por: Elewski, B.E., et al.
Publicado: (2019)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial
por: Ruperto, Nicola, et al.
Publicado: (2014)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Adalimumab for severe psoriasis in Chilean paediatric patients()()
por: Armijo Fernandez, Daniela, et al.
Publicado: (2020)

Diversity of KIR/HLA Genotypes and Their Association with Psoriasis Vulgaris in the Western Mexican Population
por: Graciano-Machuca, Omar, et al.
Publicado: (2020)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
por: Yayli, Savas, et al.
Publicado: (2013)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis
por: de Natividade, Natallia Barreiros, et al.
Publicado: (2017)

Thalamic stroke in a young adult with severe psoriasis refractory to adalimumab
por: Kadayakkara, Deepak Kana, et al.
Publicado: (2015)

Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence
por: Lombardi, G, et al.
Publicado: (2016)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab
por: Alahmari, Hana S., et al.
Publicado: (2019)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy
por: KOKOLAKIS, Georgios, et al.
Publicado: (2020)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Macrophage migration inhibitory factor gene polymorphisms (SNP ‐173 G>C and STR‐794 CATT5‐8) confer risk of plaque psoriasis: A case–control study
por: Hernández‐Bello, Jorge, et al.
Publicado: (2021)

Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous changes in a patient with psoriasis treated with adalimumab
por: Belyaeva, Elizaveta A., et al.
Publicado: (2015)

Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab
por: Fässler, Mirjam, et al.
Publicado: (2020)

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
por: Raimondo, Annunziata, et al.
Publicado: (2021)

Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis
por: Benzaquen, Michael, et al.
Publicado: (2022)

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis
por: Zhao, Zheng, et al.
Publicado: (2022)

Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab
por: Alshehri, Hamza, et al.
Publicado: (2023)

Lithium-Associated Generalized Ostraceous Psoriasis Treated with Adalimumab: A Case Report
por: Yang, Yao, et al.
Publicado: (2023)

Granuloma Annulare, a Possible Paradoxical Reaction of the Adalimumab Treatment in a Severe Case of Psoriasis Vulgaris
por: MĂRCULESCU, FLORENTINA, et al.
Publicado: (2020)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0b3qdt6juko21du1ju6h32ti0s